To detect a thiopurine methyltransferase (TPMT) deficiency and determine your risk of developing severe side effects if treated with the class of
Azathioprine has been in use for decades as an immunosuppressant treatment for various autoimmune diseases
Thiopurine S-methyltransferase (TPMT) is an important enzyme involved in AZA metabolism
Consensus guidelines recommend that patients with thiopurine S
The activity of the enzyme thiopurine methyltransferase (TPMT) is regulated by a common genetic polymorphism
Patients with thiopurine methyltransferase (TPMT) deficiency are intolerant to azathioprine, whilst carriers are at increased risk of side-effects
is linked to the thiopurine methyltransferase (TPMT) genetic polymorphism that results in Three thiopurine derivatives are used in clinical practice: thioguanine, mercaptopurine, and azathioprine (a prodrug for mercaptopurine)
In the US, 11% of the population show intermediate TPMT activity, and
Thiopurine Methyltransferase, RBC; 0092066
tube
All patients should be assessed prior to commencement of the drug, not retrospectively to ascertain the cause of an adverse reaction
Purpose Azathioprine (AZA) is widely used as an immunosuppressive drug in autoimmune diseases, but its use is limited by significant adverse drug reactions (ADRs)
These are inactive prodrugs that must be metabolized to 6-thioguanine nucleotides (6-TGN) to function
Thiopurines include three medications: 6- mercaptopurine (6-MP), 6-thioguanine (6-TG), and azathioprine
Azathioprine toxicity is related to enzyme genotype (and mutation) in renal transplant patients
The immunosuppressive drug 6-mercaptopurine (6-MP) and its prodrug azathioprine are used in the treatment of inflammatory bowel disease and other disorders of immune regulation ()